Jiarui Lin, YeZhong Zhuang, Haokai Hu, Lisheng Huang, Jinpeng Yuan, Xiaolong Wei, Muming Xu. "Neoadjuvant chemoradiotherapy plus PD-1 inhibitor (tislelizumab) for high risk and MRF+ low locally advanced rectal cancer.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e15644